Compare GSK plc (GSK) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Banco Santander SA — how do they compare? GSK plc trades at $52.77 (market cap $101.34B), while Banco Santander SA trades at $13.64 (market cap $195.14B). The key difference: Banco Santander SA is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | SAN | |
|---|---|---|
Market Cap | $101.34B | $195.14B |
Sector | Health | Financials |
52-Week High | $61.18 | $14.37 |
52-Week Low | $36.20 | $8.40 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SAN trades at $13.67, up 0.29% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q1 2026 EPS of $0.4144, beating expectations of $0.29, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value.
Outlook is positive with analyst consensus at 64% buy ratings, supported by record profitability and a dividend yield from the recent $0.15 payout. Risks include declining operating cash flow, high debt levels, and antitrust probes in Spain. The stock offers value with a P/E of 13.73 and ROE of 16.18%, but investors should monitor cash flow trends and regulatory outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
